When considered alongside our inferCNV results, these findings reinforce the concept that HER2-negative, ICD-positive tumors may represent a transitional phenotype within the HER2-driven continuum, highlighting the role of tumor cell plasticity during disease progression and therapy response. The gene discussed is ERBB2; the disease is neoplasm.